James Lynam

ORCID: 0000-0002-6742-820X

1

h-index

1

Publications

1,262

Citations

Publications

1 shown

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

James Lynam , Niall C. Tebbutt , Mark Wong +97 more

2018 The Lancet 1262 citations

Frequent Co-Authors

Niall C. Tebbutt

Royal Marsden NHS Foundation Trust

Mark Wong

Andrew Strickland

Christos S. Karapetis

Florida Hospital Cancer Institute

David Goldstein

Princess Margaret Cancer Centre

Paul L. Vasey

Researcher Info

h-index: 1
Publications: 1
Citations: 1,262

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0002-6742-820X

Impact Metrics

h-index 1

h-index: Number of publications with at least h citations each.